Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Shen, Lin"'
Publikováno v:
Clinical Breast Cancer. 21:e479-e488
Background We conducted a cost-effectiveness analysis incorporating recent phase III clinical trial (MONALEESA-7) data to evaluate the cost-effectiveness of ribociclib (RIB) as a first-line treatment for premenopausal women with hormone receptor (HR)
Autor:
Liangliang Dong, Xiaojia Huang, Shen Lin, Xiuhua Weng, Shaohong Luo, Xiongwei Xu, Xiaoting Huang, Lixian Zhong, Yiyuan Li
Publikováno v:
Pharmacogenomics. 22:809-819
Aim: To compare the cost–effectiveness of olaparib versus control treatment in metastatic castration-resistant prostate cancer patients with at least one gene mutation in BRCA1, BRCA2 or ATM from the US payer perspective. Methods: A Markov model wa
Publikováno v:
The Annals of Thoracic Surgery. 110:2055-2061
Background Randomized controlled trials have compared the early and midterm prognosis of on-pump coronary artery bypass grafting (CABG) and off-pump CABG. However the results are controversial, and there is limited information on graft patency and lo
Autor:
Lang Qin, Fengyi He, Xiaojia Li, Chaogang Chen, Xiaozhu Zhong, Rui Gao, Shen Lin, Sushi Jiang, Xiaomiao Zhao, Wenming Xu
Publikováno v:
Reproductive Sciences. 28:1101-1111
We aimed at exploring the value of neutrophil and neutrophil-to-lymphocyte ratio (NLR) as predictive risk markers for recurrent pregnancy loss (RPL) by conducting a retrospective case-control study and a systematic review and meta-analysis. This retr
Publikováno v:
Journal of Chinese Pharmaceutical Sciences. 29:542-553
Autor:
Chang-Shen Lin, Kung-Kai Kuo, Wen-Tsan Chang, King-Teh Lee, Yu-Chu Wang, Jian-Wei Huang, Lin-An Chen, Shen-Nien Wang, Shih-Chang Chuang, Wen-Lung Su
Publikováno v:
Cancer Biomarkers
Background Effective prognostic biomarkers and powerful target-therapeutic drugs are needed for improving the treatment of Hepatocellular carcinoma (HCC). Objective This study aimed to evaluate the expression of FOXM1 and Aurora-A and their prognosti
Autor:
Shen Lin, Heng Zhang, Si-Peng Chen, Chen-Fei Rao, Fan Wu, Fa-Jun Zhou, Yun Wang, Hong-Bing Yan, Ke-Fei Dou, Yong-Jian Wu, Yi-Da Tang, Li-Hua Xie, Chang-Dong Guan, Bo Xu, Zhe Zheng, Qiang Shi
Publikováno v:
Chinese Medical Journal
Chinese Medical Journal, Vol 133, Iss 11, Pp 1276-1284 (2020)
Chinese Medical Journal, Vol 133, Iss 11, Pp 1276-1284 (2020)
Background:. Imprecise interpretation of coronary angiograms was reported and resulted in inappropriate revascularization. Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score is a comprehensive system to e
Autor:
Rao Xin, Xiuhua Weng, Meiyue Li, Shen Lin, Lixian Zhong, Shaohong Luo, Xiongwei Xu, Pinfang Huang
Publikováno v:
Oncology Research
To evaluate the cost‐utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic non-small cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed to compare the lifetime cost and
Autor:
Shen Lin, Heng Zhang, Chen-Fei Rao, Si-Peng Chen, Shu-Bin Qiao, Hong-Bing Yan, Ke-Fei Dou, Yong-Jian Wu, Yi-Da Tang, Xin-Chun Yang, Zhu-Jun Shen, Jian Liu, Zhe Zheng, Ning-Ning Wang, Beijing Coronary Angiography Registry Collaborative Group
Publikováno v:
Chinese Medical Journal, Vol 133, Iss 1, Pp 1-8 (2020)
Chinese Medical Journal
Chinese Medical Journal
Background: The Chinese appropriate use criteria (AUC) for coronary revascularization was released in 2016 to improve the use of coronary revascularization. This study aimed to evaluate the association between the appropriateness of coronary revascul
Autor:
Shaohong Luo, Peili Lin, Shen Lin, Xiuhua Weng, Dongni Nian, Meiyue Li, Xiaoting Huang, Xiaojia Huang
Background: Several studies have evaluated the cost-effectiveness of treatment for advanced hepatocellular carcinoma (HCC), but the economics of atezolizumab plus bevacizumab (Ate plus Beva) remains unclear. Method: A three-state Markov model was est
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7cd59c5d1dd3b17ceacd601f7b2c940
https://doi.org/10.21203/rs.3.rs-761908/v1
https://doi.org/10.21203/rs.3.rs-761908/v1